Business · 15/10/2012Updated: 10/17/2026 · 1 min read

National Institutes of Health to Grant Exclusive License for Anti-CD22 CARs for B Cell Malignancies Treatment

Summary

The National Institutes of Health is considering granting an exclusive license to practice inventions related to anti-CD22 chimeric antigen receptors (CARs) for the treatment of B cell malignancies, as outlined in U.S. Patent Applications and patents.

Original source language: Federal Register — Health and Human ServicesOpen original release →

Add your company to Business Communicator

We monitor business sources and connect attention with companies, profiles and services available in Business Communicator.

Create a free company profile Explore businesses on Business Maps →

Create a free company profile →

Explore insights

Business insights →

Global Markets News Trade Regulation News Business Technology News Fintech for Business: Payments & Banking News Supply Chain News Central Bank Policy News

Related business signals

Business · 9/15/2026

National Cancer Institute Considers Exclusive Patent License for Engineered Cell Therapies for HPV 16 E6-Expressing Cancers

The National Cancer Institute, part of the National Institutes of Health, Department of Health and Human Services, is considering granting an exclusive patent license to MedGene Therapeutics, Inc., a Maryland-based company, to develop and commercialize engineered cell therapies for treating cancers caused by the HPV 16 E6 gene.

Read summary →

Business · 9/16/2026

NIH Proposed Collection; 60-Day Comment Request; NIH Intramural Reporting of Research Misconduct (IRRM) Web Form

The National Institutes of Health (NIH) is proposing a web-based reporting form to help the Agency Intramural Research Integrity Officer (AIRIO) assess concerns and determine appropriate next steps in evaluating allegations of research misconduct.

Read summary →

Business · 9/14/2026

NIH Proposes Enhanced Biosafety Policy for Biohazard Research

The National Institutes of Health is seeking public input on a new, comprehensive biosafety policy aimed at strengthening oversight and keeping pace with evolving biohazard risks, with the goal of ensuring gold-standard science under gold-standard biosafety conditions.

Read summary →

Business · 9/14/2026

NIH Requests Public Comment on Proposed Collection of Data for NIH Certificates of Confidentiality

The National Institutes of Health (NIH) is seeking public comment on a proposed data collection project, as required by the Paperwork Reduction Act of 1995, before submitting it to the Office of Management and Budget (OMB) for review and approval.

Read summary →

Business · 9/16/2026

Government-Owned Inventions; Availability for Licensing

The National Institute of Allergy and Infectious Diseases (NIAID) is giving notice of a government-owned invention available for licensing to achieve commercialization of federally funded research results.

Read summary →

Business · 9/15/2026

World Trade Center Health Program Denies Stroke Petitions

The World Trade Center Health Program Administrator has denied petitions to add stroke to the list of WTC-related health conditions due to insufficient evidence, and therefore will not request a recommendation from the WTC Health Program Scientific/Technical Advisory Committee or publish a proposed rule.

Read summary →